On January 3, 2023, RepliCel Life Sciences Inc. closed the transaction. The company issued 8,419,650 units at a price of CAD 0.10 per unit for gross proceeds of CAD 841,965. The transaction included participation from Each of Andrew Schutte, Peter Lowry, Peter Lewis and Gary Boddington.

The TSX Venture Exchange has accepted for filing documentation with respect to the transaction. The transaction included participation from eight placees and existing insiders for 7,869,650 units.